1. Home
  2. CRGX vs GRAL Comparison

CRGX vs GRAL Comparison

Compare CRGX & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • GRAL
  • Stock Information
  • Founded
  • CRGX 2021
  • GRAL 2016
  • Country
  • CRGX United States
  • GRAL United States
  • Employees
  • CRGX N/A
  • GRAL N/A
  • Industry
  • CRGX
  • GRAL
  • Sector
  • CRGX
  • GRAL
  • Exchange
  • CRGX Nasdaq
  • GRAL NYSE
  • Market Cap
  • CRGX 628.6M
  • GRAL 610.9M
  • IPO Year
  • CRGX 2023
  • GRAL N/A
  • Fundamental
  • Price
  • CRGX $3.70
  • GRAL $27.78
  • Analyst Decision
  • CRGX Hold
  • GRAL Hold
  • Analyst Count
  • CRGX 7
  • GRAL 2
  • Target Price
  • CRGX $4.67
  • GRAL $16.00
  • AVG Volume (30 Days)
  • CRGX 1.9M
  • GRAL 1.1M
  • Earning Date
  • CRGX 03-20-2025
  • GRAL 02-15-2025
  • Dividend Yield
  • CRGX N/A
  • GRAL N/A
  • EPS Growth
  • CRGX N/A
  • GRAL N/A
  • EPS
  • CRGX N/A
  • GRAL N/A
  • Revenue
  • CRGX N/A
  • GRAL $117,669,000.00
  • Revenue This Year
  • CRGX N/A
  • GRAL $32.48
  • Revenue Next Year
  • CRGX N/A
  • GRAL $14.72
  • P/E Ratio
  • CRGX N/A
  • GRAL N/A
  • Revenue Growth
  • CRGX N/A
  • GRAL 111.83
  • 52 Week Low
  • CRGX $3.00
  • GRAL $12.33
  • 52 Week High
  • CRGX $33.92
  • GRAL $32.65
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 20.88
  • GRAL N/A
  • Support Level
  • CRGX $3.00
  • GRAL N/A
  • Resistance Level
  • CRGX $3.88
  • GRAL N/A
  • Average True Range (ATR)
  • CRGX 0.92
  • GRAL 0.00
  • MACD
  • CRGX -1.00
  • GRAL 0.00
  • Stochastic Oscillator
  • CRGX 5.99
  • GRAL 0.00

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About GRAL GRAIL INC

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.

Share on Social Networks: